Billionaire Profile
Massimiliana Landini Aleotti & family
Global Rank
#434

Image: Public domain | via Wikimedia Commons

Massimiliana Landini Aleotti & family

CEO, Menarini Group
IT
Real-Time Net Worth
$8B
As of December 2025
Age
83
Source
Pharmaceuticals
Industry
healthcare
Citizenship
IT

Biography

Massimiliana Landini Aleotti, born in 1942, is an Italian billionaire heiress and owner of the Menarini pharmaceutical company, one of the largest pharmaceutical companies in the world. Her wealth stems from inheriting Menarini, which her late husband, Alberto Aleotti, acquired and expanded. Massimiliana, along with her children, has been instrumental in the company's growth, with her daughter, Lucia, serving as chairman, and son Alberto Giovanni as vice chairman. Menarini has a global presence in 140 countries and focuses on therapeutics and diagnostic solutions for various diseases. Massimiliana is also involved in philanthropy, supporting various social causes. Her net worth as of December 5, 2025, is estimated at $8 Billion, as reported by Forbes.

Wealth Over Time

In-Depth Profile

Early Life

Massimiliana Landini Aleotti was born in Lerici, Italy, on August 7, 1942. She holds a degree in Economics and Business from the University of Florence. She married Alberto Aleotti, who later became the owner of Menarini. Alberto Aleotti joined Menarini in 1964 and acquired the company in the early 1990s.

Rise to Success

Massimiliana's husband, Alberto, built Menarini into a leading pharmaceutical company. After Alberto's death in 2014, Massimiliana and her three children inherited Menarini. Under their guidance, the company has expanded globally, with a presence in 140 countries and over 17,000 employees. Lucia, Massimiliana's daughter, serves as the chairman, and Alberto Giovanni is the vice chairman. The Aleotti family is known for its business success and is one of the wealthiest families in Italy.

Key Business Strategies

Menarini's success is rooted in its focus on research, development, and innovation in the pharmaceutical industry. The company specializes in various therapeutic areas, including cardiovascular diseases, oncology, and infectious diseases. The company has expanded its reach through acquisitions and strategic partnerships, including entering the US oncology market.

Philanthropy

The Aleotti family is involved in philanthropic initiatives, including supporting pediatric networks and social housing projects. Menarini initiated the 'Paediatric network against ill-treatment of minors'. The family’s contributions to healthcare, education, and social causes reflect their commitment to giving back to society.

Career Milestones

1942

Born

Massimiliana Landini Aleotti was born in Lerici, Italy.

1964

Alberto Aleotti joined Menarini

Alberto Aleotti, Massimiliana's husband, began working at Menarini.

1990s

Alberto Aleotti acquired Menarini

Alberto Aleotti purchased Menarini.

2011

Lucia Aleotti became Chairman

Lucia Aleotti, Massimiliana's daughter, took over the reins of the company and became chairman. Alberto Giovanni became the vice chairman.

2014

Inherited Menarini

Massimiliana Landini Aleotti and her children inherited Menarini after the death of Alberto Aleotti.

Philanthropy & Social Impact

Child Welfare

Paediatric network against ill-treatment of minors

$1M

Menarini initiated a program in collaboration with various organizations to combat child abuse.

Social Housing

Social Housing Renovation

$0

The company is involved in a social housing renovation project in Florence, Italy, to provide housing for families in need.

Controversies & Challenges

2010

Tax Evasion Accusations

Italian tax authorities accused the family of tax evasion, but the judgement was annulled by the Italian Supreme Court in 2013.

2013

Further Tax Evasion Accusations

Massimiliana, her daughter Lucia, and her son Alberto Giovanni, were again accused of tax evasion.

2016

Corruption and Money Laundering Charges

Lucia and Alberto Giovanni were found guilty of corruption and money laundering charges, with sentences issued.